Biogen Inc (NASDAQ: BIIB) has seen a rise in its stock price by 1.38 in relation to its previous close of 219.72. However, the company has experienced a 4.33% gain in its stock price over the last five trading sessions. InvestorPlace reported 2024-04-29 that One of the best ways to keep your portfolio safe while generating consistent income is in safe, dividend-paying retirement stocks at 52-week lows. It’s even better if you’re buying into a reputable company that’s paid out dividends for years, and is on sale.
Is It Worth Investing in Biogen Inc (NASDAQ: BIIB) Right Now?
The price-to-earnings ratio for Biogen Inc (NASDAQ: BIIB) is above average at 27.82x. The 36-month beta value for BIIB is also noteworthy at -0.03. There are mixed opinions on the stock, with 13 analysts rating it as a “buy,” 8 rating it as “overweight,” 11 rating it as “hold,” and 0 rating it as “sell.”
The public float for BIIB is 144.43M, and at present, short sellers hold a 2.26% of that float. The average trading volume of BIIB on May 10, 2024 was 1.31M shares.
BIIB’s Market Performance
BIIB stock saw an increase of 4.33% in the past week, with a monthly gain of 10.52% and a quarterly increase of -7.30%. The volatility ratio for the week is 2.16%, and the volatility levels for the last 30 days are 2.56% for Biogen Inc (BIIB). The simple moving average for the last 20 days is 8.42% for BIIB stock, with a simple moving average of -7.54% for the last 200 days.
Analysts’ Opinion of BIIB
Many brokerage firms have already submitted their reports for BIIB stocks, with Needham repeating the rating for BIIB by listing it as a “Buy.” The predicted price for BIIB in the upcoming period, according to Needham is $300 based on the research report published on February 14, 2024 of the current year 2024.
Wells Fargo, on the other hand, stated in their research note that they expect to see BIIB reach a price target of $240, previously predicting the price at $315. The rating they have provided for BIIB stocks is “Equal Weight” according to the report published on February 14th, 2024.
UBS gave a rating of “Neutral” to BIIB, setting the target price at $276 in the report published on January 24th of the current year.
BIIB Trading at 5.10% from the 50-Day Moving Average
After a stumble in the market that brought BIIB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -30.34% of loss for the given period.
Volatility was left at 2.56%, however, over the last 30 days, the volatility rate increased by 2.16%, as shares surge +9.36% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +0.46% upper at present.
During the last 5 trading sessions, BIIB rose by +4.33%, which changed the moving average for the period of 200-days by -17.59% in comparison to the 20-day moving average, which settled at $206.41. In addition, Biogen Inc saw -13.92% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BIIB starting from Singhal Priya, who sale 93 shares at the price of $213.09 back on Apr 02 ’24. After this action, Singhal Priya now owns 4,886 shares of Biogen Inc, valued at $19,817 using the latest closing price.
Singhal Priya, the Head of Development of Biogen Inc, sale 262 shares at $221.23 during a trade that took place back on Feb 22 ’24, which means that Singhal Priya is holding 4,886 shares at $57,962 based on the most recent closing price.
Stock Fundamentals for BIIB
Current profitability levels for the company are sitting at:
- 0.14 for the present operating margin
- 0.73 for the gross margin
The net margin for Biogen Inc stands at 0.12. The total capital return value is set at 0.06. Equity return is now at value 8.04, with 4.56 for asset returns.
Based on Biogen Inc (BIIB), the company’s capital structure generated 0.3 points at debt to capital in total, while cash flow to debt ratio is standing at 0.25. The debt to equity ratio resting at 0.43. The interest coverage ratio of the stock is 5.33.
Currently, EBITDA for the company is 2.6 billion with net debt to EBITDA at 2.45. When we switch over and look at the enterprise to sales, we see a ratio of 4.0. The receivables turnover for the company is 4.79for trailing twelve months and the total asset turnover is 0.36. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.10.
Conclusion
In summary, Biogen Inc (BIIB) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
